Citations

Clear

3314 citation(s) found for "Yu, Alexander".

Conformation-specific RNA aptamers for phenotypic distinction between normal von Willebrand factor and type 2B von Willebrand disease
Machha, Venkata R. , Moon‐Tasson, Laurie, Tange, Julie I, Santiago-Davis, Annyoceli, Pruthi, Rajiv K. , Chen, Dong , Maher, L. James , Auton, Matthew , Tischer, Alexander , Moon-Tasson, Laurie, Tange, Julie, Chen, Dong , III, Louis James Maher , Auton, Matthew , Tischer, Alexander

Mayo Clinic

NAR Molecular Medicine | November 24, 2024 | Volume: 1 | Issue: 4 | Pages: No page available

10.1093/narmme/ugae021 | PMID 39719968 Get It

Abstract The A1 domain in Von Willebrand Factor (VWF) initiates coagulation through binding to platelet glycoprotein GPIbα receptors. Von Willebrand Disease (VWD)-Mutations in A1 that either impair (type 2M) or enhance (type 2B) platelet adhesion to VWF can locally destabilize and even misfold the domain. We leveraged misfolding in the gain-of-function type 2B VWD phenotype as a target, distinct from the normal conformation. Two nuclease-resistant 2′-fluoropyrimidine RNA aptamers were selected to discriminate normal A1 domains from a type 2B V1314D A1 variant in a glycosylated A1A2A3 tri-domain VWF-fragment. Two aptamers, W9 and V1, were isolated that selectively recognize, bind, and inhibit the A1–GPIbα interaction with WT A1A2A3 and V1314D A1A2A3, respectively. These aptamers were tested against their respective recombinant targets, plasma VWF, VWF concentrates, and patient plasma with the heterozygous type 2B VWD R1306W variant using clinical assays, surface plasmon resonance and inhibition assays of platelet adhesion to recombinant A1 and A1A2A3 domains under shear stress. The specificity of W9 and V1 aptamers confirms that pathological conformations of VWD Type 2B proteins are different from normal VWF. The availability of aptamers that distinguish normal plasma-derived VWF from VWD suggests potential applicability in clinical diagnosis of severe gain-of-function phenotypes.
Prothrombotic antibodies targeting the spike protein's receptor-binding domain in severe COVID-19
Zhu, Wen , Zheng, Yongwei , Yu, Mei , Witman, Nathan , Zhou, Lu , Wei, Jianhui, Zhang, Yongguang , Nguyen, Christine , Wang, David , Janecke, Rae , Padmanabhan, Anand , White, Gilbert, Fields, Alexander T. , Kornblith, Lucy Z. , Aster, Richard H. , Zhu, Jieqing , Jobe, Shawn M. , Graham, Mary Beth, Wang, Demin , Wen, Renren , Topchyan, Paytsar , Nguyen, Christine , Wang, David , Janecke, Rae , Padmanabhan, Anand , Baumann Kreuziger, Lisa , Hari, Parameswaran , Gu, Tongjun , Kornblith, Lucy Z , Aster, Richard , Zhu, Jieqing , Cui, Weiguo , Jobe, Shawn , Graham, Mary Beth , Wang, Demin , Wen, Renren , Zhou, Lu , Kreuziger, Lisa Baumann , White, Gilbert C., Hari, Parameswaran , Cui, Weiguo

Mayo Clinic

Blood | November 22, 2024 | Volume: 145 | Issue: 6 | Pages: 635-647

10.1182/blood.2024025010 | PMID 39576992 Get It

Abstract Thromboembolic complication is common in severe coronavirus disease 2019 (COVID-19), leading to an investigation into the presence of prothrombotic antibodies akin to those found in heparin-induced thrombocytopenia (HIT). In a study of samples from 130 hospitalized patients, collected 3.6 days after COVID-19 diagnosis, 80% had immunoglobulin G (IgG) antibodies recognizing complexes of heparin and platelet factor 4 (PF4; PF4/H), and 41% had antibodies inducing PF4-dependent P-selectin expression in CpG oligodeoxynucleotide–treated normal platelets. Unlike HIT, both PF4/H-reactive and platelet-activating antibodies were found in patients with COVID-19 regardless of recent heparin exposure. Notably, PF4/H-reactive IgG antibodies correlated with those targeting the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 spike protein. Moreover, introducing exogenous RBD to or removing RBD-reactive IgG from COVID-19 plasma or IgG purified from COVID-19 plasma significantly reduced their ability to activate platelets. RBD-specific antibodies capable of platelet activation were cloned from peripheral blood B cells of patients with COVID-19. These antibodies possessed sequence motifs in the heavy-chain complementarity-determining region 3 (HCDR3), resembling those identified in pathogenic HIT antibodies. Furthermore, IgG+ B cells having these HCDR3 signatures were markedly expanded in patients with severe COVID-19. Importantly, platelet-activating antibodies present in patients with COVID-19 were associated with a specific elevation of platelet α-granule proteins in the plasma and showed a positive correlation with markers for inflammation and tissue damage, suggesting a functionality of these antibodies in patients. The demonstration of functional and structural similarities between certain RBD-specific antibodies in patients with COVID-19 and pathogenic antibodies typical of HIT suggests a novel mechanism by which RBD-specific antibodies might contribute to thrombosis in COVID-19.
LTBK-02. EVALUATION OF PAXALISIB IN GBM AGILE PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
Mellinghoff, Ingo K. , Berry, Donald A. , Buxton, Meredith , Colman, Howard , Gordon, Gary, Lassman, Andrew B. , Lim, Michael , Perry, James , Wen, Patrick Y. , Yung, W.K. Alfred , Berry, Nicholas , Graves, Todd, Detry, Michelle A. , Hyddmark, Emma Maria Viktoria, Johnsson, Adam, Kling, Heather M., Powell, Ashley A., Untch, Sarah, Aquilanti, Elisa , Blondin, Nicholas, Boulmay, Brian C., Fuente, Macarena de la, Lobbous, Mina , Mikkelsen, Tom , Newton, Herbert B. , Schiff, David , Sherman, Wendy, Weathers, Shiao-Pei, Friend, John, Lee, E., Mellinghoff, Ingo K , Cloughesy, Timothy F. , Alexander, Brian M. , Cavenee, Webster K. , Colman, Howard , Groot, John de , Ellingson, Benjamin M. , Khasraw, Mustafa , Sulman, Erik P. , Weller, Michael , Wen, Patrick Yung , Johnsson, Adam, McGlothlin, Anna , Powell, Ashley, Drappatz, Jan , Jordan, Justin T. , Kaley, Thomas , Owen, Scott , Peters, Katherine B. , Schiff, David, Weathers, Shiao‐Pei , Youssef, Michael , Friend, John

Mayo Clinic

Neuro-Oncology | November 22, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii1-viii1

10.1093/neuonc/noae165.1302 Get It

Abstract GBM AGILE(NCT03970447) is a phase 2/3 Bayesian adaptive registration platform trial testing multiple therapies against a common control. Paxalisib, a PI3K/mTOR inhibitor, is the 3rd arm in the trial to conclude evaluation. METHODS Paxalisib was open to patients with newly diagnosed unmethylated (NDU) and recurrent (RD) glioblastoma, with three possible signatures: NDU, RD, and All(NDU+RD). Arm enrollment occurred Dec2020 through May2022. Control patients were enrolled from study initiation (July2019) and were treated with temozolomide(NDU) or lomustine(RD). GBM AGILE investigational arms have 1 or 2 stages, with adaptive randomization in stage 1 and fixed randomization if arms continue to stage 2. Efficacy is based on OS hazard ratio(HR) of Arm/Control. Efficacy goal is final Bayesian probability ≥ 98% for HR<1.00 in combined Stages. An Arm continues to Stage 2 if Bayesian predictive power (PP) ≥ 0.8. An Arm stops accruing in Stage 1 if it reaches maximal sample size(N) or does not meet a minimum efficacy threshold (PP<0.25 for all signatures when N>50). Clinical cut-off is 12 months after accrual stops. The maximum N for paxalisib was approximately 150(Stage 1) and 50(Stage 2). RESULTS After paxalisib reached >150 patients in Stage 1, accrual stopped [Paxalisib/control N 54/75(NDU), 100/188(RD)]. Neither PP thresholds for moving to Stage 2 nor stopping for minimum efficacy were met. Following an unplanned public disclosure that the arm did not continue to stage 2, clinical cut-off for final analysis (planned May2023) was updated to public disclosure date (August2022). At final analysis mean HRs were 0.89(NDU), 1.25(RD), 1.05(All), probabilities of HR<1.00 of 0.72(NDU), 0.076(RD), 0.398(All). Model estimated median OS paxalisib/control (months) were 14.77/13.84(NDU) and 8.58/10.06(RD). CONCLUSION Paxalisib did not show survival benefit over cumulative control in final primary analysis; additional secondary analyses are being considered. GBM AGILE continues to rapidly and efficiently assess therapies in ND and RD glioblastoma.
Application of the Reverse Pulse Technique for Worst Case Transient Analysis in HPC PDN Design
Smutzer, Chad M., Keuseman, Jordan R., Hickman, Alexander P., Haider, Clifton R. , Hickman, Alexander P.

Mayo Clinic

2024 IEEE 33rd Conference on Electrical Performance of Electronic Packaging and Systems (EPEPS) | November 21, 2024 | Volume: No volume available | Issue: No issue available | Pages: 1-3

10.1109/epeps61853.2024.10754562 Get It

Developing a Carotid Pseudoaneurysm Model in Swine
Banaskiewicz, Karolina , Price, Colin, Benike, Amy, Dragomir‐Daescu, Dan , Oliver, Alexander A , Treffalls, Rebecca N, Dragomir-Daescu, Dan, Treffalls, Rebecca N. , Price, Colin, Morrison, Jonathan J.

Mayo Clinic

Journal of Endovascular Therapy | November 21, 2024 | Volume: 33 | Issue: 3 | Pages: 1148-1156

10.1177/15266028241297066 | PMID 39569621 Get It

Background: Traumatic carotid artery pseudoaneurysms (PSAs) represent a vascular anomaly with potential for serious complications, including stroke. Traditional treatments involve endovascular stenting, which may not be ideally suited to otherwise healthy vessels that have the potential to remodel. Given the limitations of smaller animal models in replicating human vasculature and the need for improved treatment modalities, this study introduces a novel swine model for the creation and evaluation of carotid PSAs. Methods: The PSAs were created from bovine dura and anastomosed in an end-to-side fashion to bilateral carotid arteries. The PSAs were radiologically followed up post-operatively and were harvested at 3 and 10 days for histological analysis. Results: Pseudoaneurysms were successfully created in both animals without intra-operative or immediate post-operative complications. Radiological analysis showed well-perfused PSAs with intra-aneurysmal turbulence, hemodynamically mimicking human carotid artery PSAs. There was no evidence of thrombus or arterial stenosis. Histological examinations revealed thrombus maturation and tight anastomosis of the PSA sac with the native artery. Conclusions: This PSA swine model offers a replicable, cost-effective, and easily implemented tool with the potential to advance carotid PSA management and educational efforts in vascular surgery. Clinical Impact The model presented in this methodology paper allows for a standardized PSA animal model allowing for the standardization of a clinical entity which is frequently heterogenenous in morphology. This can allow for the development of new therapies or provide a ground truth for computer modelling for further in silico study.
Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma
Sullivan, Ryan J. , Najjar, Yana G. , Akkooi, Alexander C. J. van , Menzies, Alexander M, Long, Georgina V, Taylor, Amelia M., Haanen, John, Zijlker, Lisanne P. , Davis, Keith L. , Karanth, Siddharth , Norton, Deborah , Connolly, Lucy, Long, Georgina V. , Karanth, Siddharth , Long, Georgina V , Weber, Jeffrey S. , Haque, Waqas Zia , Markovic, Svetomir N. , Salama, April K.S. , Mehmi, Inderjit , Menzies, Alexander M , Haanen, John B A G , Connolly, Lucy

Mayo Clinic

The Oncologist | November 19, 2024 | Volume: 30 | Issue: 3 | Pages: No page available

10.1093/oncolo/oyae289 | PMID 39560953 Get It

Abstract Background In BRAF-mutated high-risk melanoma, targeted therapy (BRAF/MEK inhibitors) and checkpoint inhibitor (CPI) immunotherapy have durable benefits as first-line (1L) adjuvant therapy. Based on differing action mechanisms of BRAF/MEK inhibitors and CPI immunotherapies, there is interest in evaluating the activity of 2L adjuvant targeted therapy in decreasing the risk of subsequent recurrence after repeat resection following relapse on/after 1L adjuvant CPI. Patients and methods This was a retrospective review of BRAF V600-mutated resected stage III/IV melanoma patients in the United States, Australia, and The Netherlands who received 1L adjuvant CPI immunotherapy, relapsed locoregionally/distantly, were again resected to no evidence of disease, and received dabrafenib/trametinib (dab/tram) as 2L adjuvant therapy. The primary endpoint was relapse-free survival (RFS) from initiation of 2L adjuvant dab/tram (RFS-2), analyzed via Kaplan-Meier methods. Results Thirty-eight patients were included (median age 50 years, 63% male, 87% stage III, median follow-up 19 months from 2L dab/tram initiation). Median dab/tram duration was 10.1 months (range: 1 day–22.7 months), with half discontinuing due to progression or adverse events. Median (95% CI) RFS-2 was 18.9 (14.9–28.1) months, with 91%, 81%, and 58% remaining relapse-free at 6, 12, and 18 months, respectively. Most patients remained distant metastasis-free at 6, 12, and 18 months (97%, 85%, and 71%, respectively). Two patients were deceased at the last follow-up, with 97% alive at 18 months. Conclusions Over 80% of patients remained relapse- and metastasis-free at 12 months after 2L dab/tram initiation, with only 2 deaths observed. Dab/tram appears to have activity in the 2L adjuvant setting, although more follow-up is required.
Radiographic Enhancement of Lymph Nodes 9 Months after Omental Lymph Node Transfer
Shrout, Max A., Plonkowski, Alexander T., Morris, Bryn E., Rebecca, Alanna M. , Plonkowski, Alexander T. , Flug, Jonathan A.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | November 18, 2024 | Volume: 12 | Issue: 11 | Pages: e6305

10.1097/gox.0000000000006305 | PMID 39559267 Get It

Lymphedema is a frequent complication of breast cancer treatment. As the survival rates of breast cancer continue to increase, the number of women with lymphedema will also increase. Surgical treatment of lymphedema has made significant advances during the past 20 years, and our understanding of these procedures continues to evolve. Vascularized lymph node transfer is an increasingly popular option for surgical treatment of lymphedema; however, the mechanism behind symptomatic relief is not fully understood. A proposed theory for improvement in lymphedema symptoms is lymphangiogenesis and spontaneous regeneration of lymphatic vessels, the timing and degree of which are not well defined. We present the case of a 40-year-old woman with a 10-year history of right upper extremity lymphedema secondary to bilateral mastectomy and right axillary lymph node dissection, who subsequently underwent vascularized omental lymph node transfer and lymphovenous bypass with radiographic evidence of spontaneous lymphatic reconnection within 9 months. To our knowledge, this is the earliest reported radiographic evidence of lymphatic regeneration in a human subject to date, adding to the growing body of evidence to support the therapeutic benefits of vascularized lymph node transfers.
Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial
Judge, Daniel P. , Gillmore, Julian D. , Ambardekar, Amrut V. , Cappelli, Francesco , Fontana, Marianna , Grodin, Justin L. , Grogan, Martha , Hanna, Mazen, Masri, Ahmad , Nativi-Nicolau, José , Sarswat, Nitasha , Shah, Keyur, Cao, Xiaofan, Wang, Kevin , Tamby, Jean‐François, Katz, Leonid , Sinha, Uma, Fox, Jonathan C. , Maurer, Mathew S. , Alexander, Kevin M , Ambardekar, Amrut V , Cappelli, Francesco , Fontana, Marianna , Garcia-Pavia, Pablo , Grodin, Justin L , Grogan, Martha , Masri, Ahmad , Nativi-Nicolau, Jose , Obici, Laura , Sarswat, Nitasha , Soman, Prem , Lystig, Ted , Fox, Jonathan C , Maurer, Mathew S , Gillmore, Julian D , Judge, Daniel P , Hanna, Mazen, Obici, Laura , Poulsen, Steen Hvitfeldt , Pecoraro, Maria Lucia

Mayo Clinic

Circulation | November 18, 2024 | Volume: 151 | Issue: 9 | Pages: 601-611

10.1161/circulationaha.124.072771 | PMID 39556242 Get It

BACKGROUND: In the phase 3 randomized controlled study ATTRibute-CM (Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy), acoramidis, a transthyretin stabilizer, demonstrated significant efficacy on the primary end point. Participants with transthyretin amyloid cardiomyopathy who completed ATTRibute-CM were invited to enroll in an open-label extension study (OLE). We report the efficacy and safety data of acoramidis in participants who completed ATTRibute-CM and enrolled in the ongoing OLE. METHODS: Participants who previously received acoramidis through month 30 in ATTRibute-CM continued to receive it (continuous acoramidis), and those who received placebo through month 30 were switched to acoramidis (placebo to acoramidis). Participants who received concomitant tafamidis in ATTRibute-CM were required to discontinue it to be eligible to enroll in the OLE. Clinical efficacy outcomes analyzed through month 42 included time to event for all-cause mortality (ACM) or first cardiovascular-related hospitalization (CVH), ACM alone, first CVH alone, ACM or recurrent CVH, change from baseline in NT-proBNP (N-terminal pro-B-type natriuretic peptide), 6-minute walk distance, serum transthyretin, and Kansas City Cardiomyopathy Questionnaire Overall Summary score. Safety outcomes were analyzed through month 42. RESULTS: Overall, 438 of 632 participants in ATTRibute-CM completed treatment, and 389 enrolled in the ongoing OLE (263 continuous acoramidis and 126 placebo to acoramidis). The hazard ratio for ACM or first CVH was 0.57 (95% CI, 0.46–0.72) at month 42 based on a stratified Cox proportional hazards model ( P <0.0001) favoring continuous acoramidis. Similar analyses were performed on ACM alone and first CVH alone, with hazard ratios of 0.64 (95% CI, 0.47–0.88) and 0.53 (95% CI, 0.41–0.69), respectively, at month 42. Treatment effects for NT-proBNP and 6-minute walk distance also favored continuous acoramidis. On initiation of open-label acoramidis in the placebo-to-acoramidis arm, there was a prompt increase in serum transthyretin. Quality of life assessed by Kansas City Cardiomyopathy Questionnaire Overall Summary score was well preserved in continuous-acoramidis participants compared with the placebo-to-acoramidis participants. No new clinically important safety issues were identified in this long-term evaluation. CONCLUSIONS: Early initiation and continuous use of acoramidis in the ATTRibute-CM study through month 42 of the ongoing OLE study were associated with sustained clinical benefits in a contemporary transthyretin amyloid cardiomyopathy cohort, with no clinically important safety issues newly identified. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04988386.
Abstract Sa303: Active Decompression during Automated Head-up Cardiopulmonary Resuscitation
Pourzand, Pouria , Moore, Johanna , Suresh, Mithun , Salverda, Bayert, Hai, Hamza, bachista, kerry, Lurie, Keith G. , Metzger, Anja, Kaizer, Alexander , Duval, Sue

Mayo Clinic

Circulation | November 14, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.sa303 Get It

Background: Active compression-decompression cardiopulmonary resuscitation (ACD-CPR) combined with an impedance threshold device (ITD) and controlled head-up positioning, collectively termed AHUP-CPR, is associated with improved outcomes compared with conventional CPR (C-CPR). Active decompression (AD) forcibly lifts the anterior chest wall with suction after each compression, while the ITD simultaneously impedes airflow into the lungs. AD and ITD synergistically lower intrathoracic pressure during decompression, improving venous return, ventricular refilling and cardiac output. Concurrently, head-up positioning lowers intracranial pressures and improves cardiac preload. This pig study focused on the physiological role of AD during AHUP-CPR, simulating real clinical scenarios. Methods: Ten male and female farm pigs (~40 kg) were anesthetized, intubated and ventilated. Hemodynamic parameters, end-tidal CO2 (ETCO2), and biventricular pressure-volume loops were recorded continuously. Ventricular fibrillation was induced and left untreated for 10 mins. Then, after 2 min of automated C-CPR in the flat position, AHUP-CPR with a 3 cm lift above the neutral position of the chest was performed for 13 min. AD was then abruptly discontinued, restarted 1 min later, and increased incrementally every min to up to 4 cm of active lift. Data were analyzed with a linear mixed-effects model, using random intercepts for individual pigs. Results: Upon cessation of AD, coronary and cerebral perfusion pressures, compression and decompression aortic pressures, compression right atrial pressure, ETCO2, right and left ventricular preload, compliance, stroke volume and cardiac output all decreased immediately and significantly (p<0.01), whereas decompression right atrial and biventricular pressures increased. With restoration of AD, physiological parameters returned to ≥ 90% of pre-AD discontinuation values (Figures 1 and 2). Conclusion: Full chest wall lift, achieved with > 3 cm of AD, was needed to maintain and optimize hemodynamics during AHUP-CPR in pigs. After pausing AD, incremental restoration of AD resulted in nearly complete restoration of peripheral and central hemodynamic measures. These observations support the benefit of and need for ≥3 cm of AD to optimize AHUP-CPR. Effective means to generate ≥3 cm of AD should be considered when implementing and developing AHUP-CPR devices to optimize outcomes.
Abstract Sa1109: Aerobic Capacity of Adults with Fontan Palliation: Disease-specific Reference Values and Relationship to Outcomes
Ali, Ahmed E. , Egbe, Alexander , Goda, Ahmed, Abozied, Omar

Mayo Clinic

Circulation | November 14, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.sa1109 Get It

Background: Patients with Fontan palliation have reduced aerobic capacity because of impaired cardiac, pulmonary, and skeletal muscle function. However, the assessment of aerobic capacity in this population still relies on comparisons with people without cardiovascular disease, rather than comparison with the expected aerobic capacity of other Fontan patients. The purpose of this study was to determine the expected aerobic capacity of adults with Fontan palliation. Method: Adults with Fontan palliation who underwent cardiopulmonary exercise test at Mayo Clinic (2003-2023) were stratified into quartiles based on the predicted peak VO 2 . We assessed the correlates of predicted peak VO 2 , and the relationship between predicted peak VO 2 quartiles and cardiovascular outcomes (death/transplant). Results: Of 323 patients (age 29±9 years; 177 [55%] men), the median peak VO2 was 19.1 (15.2 - 23.9) ml/kg/min, and this corresponds to a predicted peak VO 2 of 51% (range 19 -88; interquartile range 41 - 62). The correlates of higher predicted peak VO 2 were smaller body mass index, higher systemic saturation, and lower Fontan pressures. The top, 2 nd ,3 rd , and bottom quartile of predicted peak VO 2 corresponds to predicted peak VO 2 of 63-88%, 51-62%, 41-50%, and 19-40%, respectively. Using the top quartile as the reference, the 3 rd quartile (HR 1.13, 95% CI 1.03-1.28, p=0.02), and 4 th quartile were associated with a higher risk of death/transplant (HR 1.32, 95% CI 1.16-1.69, p<0.001). Conclusions: The results of the current study would help calibrate the interpretation of exercise test data in adults with Fontan palliation and improve risk stratification in this population.